Subscribe

Fusion Antibodies plc (FAB.L)

GBp10.75 +0.00 (+0.00%)
GB LSE Healthcare Biotechnology
Address 1 Springbank Road BT17 0QL
Belfast, GB
CEO Adrian Robert Kinkaid
Website fusionantibodies.com
IPO 2017-12-18
ISIN GB00BDQZGK16

Explore sections of this company profile

Description

Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
GBp10.75 +0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
442.7K
Beta
1.22
Float Shares
99.08M
Free Float %
79.2%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-1.92% -1.92% -8.93% -8.93% +0.00% -8.93% +109.02% +112.50% -90.49% -89.68% -89.68%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
10.75
Ratings Trend (MoM)
Rating 2026-05 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-3.86
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Biotechnology: +1.6%
    +73.0% ★ Q3'25: +54.9% (vs Q3'23)
  • ✗
    EPS growth Biotechnology: +29.7%
    +55.4% ★ Q3'25: +84.6% (vs Q3'23)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    -80.7% Q3'25: -75.8% (vs Q3'23)
  • ✗
    EBIT margin Biotechnology: +0.0%
    -87.8% Q3'25: -64.2% (vs Q3'23)
  • ✗
    ROIC Biotechnology: -16.1%
    -523.0% Q3'25: -175.6% (vs Q3'23)
  • ✗
    Share dilution Biotechnology: -3.4%
    +72.6% Q3'25: +143.5% (vs Q3'23)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    -0.01× Q3'25: -0.35× (vs Q3'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (1.20) × ERP
WACC = 100% × Ke + 0% × Kd (15.0%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 10.75
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Mar 2018
actual 		Mar 2019
actual 		Mar 2020
actual 		Mar 2021
actual 		Mar 2022
actual 		Mar 2023
actual 		Mar 2024
actual 		Mar 2025
actual 		Mar 2026
1 Rev. Ana.
1 EPS Ana. 		Mar 2027
1 Rev. Ana.
1 EPS Ana.
Revenue
2.69M
est: 2.75M (-2.2%)
2.18M
est: 5.61M (-61.1%)
3.90M
est: 3.80M (+2.5%)
4.17M
est: 4.00M (+4.2%)
4.80M
est: 4.73M (+1.4%)
2.90M
est: 2.85M (+1.8%)
1.14M
est: 1.14M (-0.4%)
1.97M
est: 1.96M (+0.3%)
2.13M
2.13M – 2.13M
+8.7% YoY
2.10M
2.10M – 2.10M
-1.4% YoY
EBITDA
-636.9K
est: -1.61M (+60.5%)
-1.06M
est: -3.28M (+67.6%)
-431.0K
est: -2.23M (+80.6%)
-532.0K
est: -2.34M (+77.3%)
-573.0K
est: -2.77M (+79.3%)
-2.48M
est: -1.67M (-48.7%)
-2.07M
est: -661.8K (-212.0%)
-1.62M
est: -1.15M (-41.4%)
-1.25M
-1.25M – -1.25M
-8.7% YoY
-1.23M
-1.23M – -1.23M
+1.4% YoY
EBIT
-706.5K
est: -1.89M (+62.6%)
-1.50M
est: -3.85M (+61.2%)
-1.05M
est: -2.61M (+59.7%)
-1.25M
est: -2.75M (+54.7%)
-1.32M
est: -1.22M (-8.7%)
-2.86M
est: -1.96M (-45.7%)
-2.28M
est: -1.51M (-51.5%)
-1.73M
est: -1.35M (-28.1%)
-1.46M
-1.46M – -1.46M
-8.7% YoY
-1.44M
-1.44M – -1.44M
+1.4% YoY
Net Income
-699.9K
-1.26M
-697.0K
est: -3.74M (+81.4%)
-2.90M
est: -5.56M (+47.9%)
-1.20M
est: -4.60M (+73.9%)
-2.60M
est: -881.8K (-194.4%)
-2.23M
est: -992.0K (-124.4%)
-1.71M
est: -1.44M (-19.1%)
-671.2K
-671.2K – -671.2K
+53.3% YoY
-862.9K
-862.9K – -862.9K
-28.6% YoY
SGA
1.41M
est: 2.35M (-40.0%)
2.40M
est: 4.78M (-49.8%)
1.88M
est: 3.24M (-42.1%)
2.08M
est: 3.41M (-39.1%)
2.35M
est: 3.32M (-29.2%)
2.23M
est: 2.43M (-8.3%)
1.77M
est: 972.1K (+82.4%)
1.86M
est: 1.67M (+11.3%)
1.82M
1.82M – 1.82M
+8.7% YoY
1.79M
1.79M – 1.79M
-1.4% YoY
EPS
-0.04
-0.06
-0.03
est: -0.04 (+19.0%)
-0.11
est: -0.06 (-89.7%)
-0.05
est: -0.05 (+3.5%)
-0.10
est: -0.10 (-5.1%)
-0.04
est: -0.03 (-29.4%)
-0.02
est: -0.02 (-19.3%)
-0.01
-0.01 – -0.01
+53.3% YoY
-0.01
-0.01 – -0.01
-28.6% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-28 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-27 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-26 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-22 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-21 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-20 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-19 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-18 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-15 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-14 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-13 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-12 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-11 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-08 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-07 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-06 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-05 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-01 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-30 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-29 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-28 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-27 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-24 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-23 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-22 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-21 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-20 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-17 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-16 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-3.07M
OE per share TTM
-0.05
Owner's Yield
-21.28%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
25.7%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-63.9K
Shares Outstanding
125.02M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Adrian Kinkaid Chief Executive Officer & Director 219.0K male
Richard John Buick Chief Scientific Officer & Director 156.0K —
Nicola Hamilton Operations Manager — female
Stephen Smyth Company Secretary, Interim Chief Financial Officer & Director — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology